Lb Pharmaceuticals (LBRX) EBITDA (2024 - 2026)
Lb Pharmaceuticals (LBRX) posted quarterly EBITDA of $5.4 million for Q1 2026, up 201.76% year-over-year from $1.8 million in Q1 2025, and up 147.53% quarter-over-quarter from -$11.3 million in Q4 2025.
Powered by 
Analysis
Lb Pharmaceuticals (LBRX) EBITDA (2024 - 2026) Analysis & Trends
Lb Pharmaceuticals' EBITDA history runs 3 years deep, the most recent figure standing at $5.4 million for Q1 2026.
- In Q1 2026, EBITDA rose 201.76% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at -$14.1 million (changed N/A YoY), while the FY2025 annual figure was $4.5 million, up 111.25% from the prior year.
- EBITDA for Q1 2026 stood at $5.4 million, up from -$11.3 million in the prior quarter.
- The five-year high for EBITDA was $5.4 million in Q1 2026, with the low at -$14.2 million in Q3 2024.
- The 3-year median for EBITDA is -$5.2 million (2024), against an average of -$5.6 million.
- The sharpest annual moves came in 2025 and 2026: EBITDA plunged 122.66% in 2025, then surged 201.76% in 2026.
- Lb Pharmaceuticals' EBITDA stood at -$5.1 million in 2024, then slumped by 122.66% to -$11.3 million in 2025, then surged by 147.53% to $5.4 million in 2026.
- Business Quant data shows LBRX's EBITDA at $5.4 million in Q1 2026, -$11.3 million in Q4 2025, and -$2.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Lb Pharmaceuticals | 1.49 Bn | 1.49 Bn | - | -51.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -51.60 Mn |
| Mar 31, 2026 | -19.05 Mn |
| Dec 31, 2025 | -11.47 Mn |
| Sep 30, 2025 | -3.56 Mn |
| Jun 30, 2025 | -4.87 Mn |
| Mar 31, 2025 | -5.31 Mn |
| Dec 31, 2024 | -5.07 Mn |
| Sep 30, 2024 | -14.18 Mn |